Aurion Biotech, Inc.

Aurion Biotech, Inc. is a clinical-stage biotechnology company focused on restoring vision through regenerative cell therapies. Founded in 2021 with offices in Seattle, Boston and Tokyo, Aurion develops AURN001, a cultured corneal endothelial cell therapy to treat corneal edema from endothelial dysfunction. The company has advanced clinical programs, regulatory designations, and commercial activity in Japan, aiming to scale donor-cell culture processes for global corneal care.